Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)

NCT01671111 | Terminated Phase 2 Results

• 2 other identifiers: SPD602-3012011-006322-25
• Study Type: interventional
• Target: 30
• Locations: 5 countries
• Sites: 9

Brief Summary

The purpose of this extension study is to evaluate SSP-004184AQ in patients with transfusional iron overload and to provide data on long term safety and efficacy. SSP-004184AQ is an iron chelator under development for chronic daily oral administration to patients with transfusional iron overload

Conditions

Iron Overload Due to Repeated Red Blood Cell Transfusions

Outcome Measures

Primary Outcomes (6)

• Change From Baseline in Ferriscan® R2 Liver Iron Concentrations (LIC) at Week 24 (Cycle 1)

  Efficacy of SSP-004184 was assessed by determining LIC. Abdominal magnetic resonance imaging (MRI) data were collected by using FerriScan R2 standard procedures and used to determine LIC. A negative change from baseline indicates that LIC decreased. A cycle consisted of 8 standard 6-weekly visits and the cycles were repeated each year for the duration of the study.

  Baseline, Week 24 (Cycle 1)

• Change From Baseline in Ferriscan® R2 Liver Iron Concentrations (LIC) at Week 48 (Cycle 1)

  Efficacy of SSP-004184 was assessed by determining LIC. Abdominal MRI data were collected by using FerriScan R2 standard procedures and used to determine LIC. A negative change from baseline indicates that LIC decreased. A cycle consisted of 8 standard 6-weekly visits and the cycles were repeated each year for the duration of the study.

  Baseline, Week 48 (Cycle 1)

• Change From Baseline in Ferriscan® R2 Liver Iron Concentrations (LIC) at Week 24 (Cycle 2)

  Efficacy of SSP-004184 was assessed by determining LIC. Abdominal MRI data were collected by using FerriScan R2 standard procedures and used to determine LIC. A negative change from baseline indicates that LIC decreased. A cycle consisted of 8 standard 6-weekly visits and the cycles were repeated each year for the duration of the study.

  Baseline, Week 24 (Cycle 2)

• Change From Baseline in Cardiac T2* Values at Week 24 (Cycle 1)

  The efficacy of SSP-004184 was assessed by determining cardiac iron load. Cardiac MRI data were collected by using T2\* standard procedures and used to determine iron load. A negative change from baseline indicates that iron load increased. A cycle consisted of 8 standard 6-weekly visits and the cycles were repeated each year for the duration of the study.

  Baseline, Week 24 (Cycle 1)

• Change From Baseline in Cardiac T2* Values at Week 48 (Cycle 1)

  The efficacy of SSP-004184 was assessed by determining cardiac iron load. Cardiac MRI data were collected by using T2\* standard procedures and used to determine iron load. A negative change from baseline indicates that iron load increased. A cycle consisted of 8 standard 6-weekly visits and the cycles were repeated each year for the duration of the study.

  Baseline, Week 48 (Cycle 1)

• Change From Baseline in Cardiac T2* Values at Week 24 (Cycle 2)

  The efficacy of SSP-004184 was assessed by determining cardiac iron load. Cardiac MRI data were collected by using T2\* standard procedures and used to determine iron load. A negative change from baseline indicates that iron load increased. A cycle consisted of 8 standard 6-weekly visits and the cycles were repeated each year for the duration of the study.

  Baseline, Week 24 (Cycle 2)

Secondary Outcomes (1)

• Change From Baseline in Serum Ferritin Values at Specified Visits

  Baseline, Weeks 24 and 48 of Cycle 1, Week 24 of Cycle 2

Study Arms (1)

SSP-004814AQ

EXPERIMENTAL

Drug: SSP-004184AQ

Interventions

SSP-004184AQ DRUG

Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or "active" form)

Also known as: SPD602

SSP-004814AQ

Eligibility Criteria

• Age: 6 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects and/or parents willing and able to sign the approved informed consent/and assent (based on institutional guidelines).
• An understanding, ability, and willingness to fully comply with study procedures and restrictions.
• Has either completed a previous SSP-004184AQ study or prematurely discontinued from (with agreement from the Investigator and Shire physician) from one of the SSP-004184AQ studies.
• If applicable, female subjects should be either:
• Post-menopausal (12 consecutive months of spontaneous amenorrhea), or
• Surgically sterile, or
• Females of child-bearing potential must have a negative urine pregnancy test at the Qualification and Enrollment Visit prior to dosing on Day 1. Females of child-bearing potential must agree to abstain from sexual activity that could result in pregnancy or agree to use acceptable methods of contraception.
• For subjects that did not transition directly from their feeder protocol and have initiated treatment with a chelator other than SSP-004184AQ:
• Willing to discontinue all existing iron chelation therapies for a minimum period of 1 to 5 days prior to first dose of SSP-004184AQ.
• Serum ferritin greater than 500 ng/mL at the Qualification and Enrollment Visit.
• Liver iron concentration (LIC) greater than or equal to 2.0 mg iron per g (equivalent dry weight, liver) determined by FerriScan® R2 MRI at the Qualification and Enrollment Visit (Day -28 to Day -8).
• (Note: Younger subjects for whom MRI is not feasible will be considered iron overloaded on the basis of serum ferritin only.) - Mean of the previous 3 pre-transfusion hemoglobin concentrations greater than or equal to 7.5 g/dL.

You may not qualify if:

• Unwilling to remain off all other existing chelation therapies during SSP-004184AQ dosing and for up to 24 hours from last dose.
• A history of non-compliance in a prior FerroKin/Shire-sponsored SSP-004184AQ study (excluding dose suspensions that were medically warranted).
• Cardiac MRI T2\* less than 10.0 milliseconds at the Qualification and Enrollment Visit.
• Cardiac left ventricular ejection fraction less than 50% at the Qualification and Enrollment Visit by MRI or below the locally determined normal range by echocardiography if MRI information is not available.
• Evidence of clinically relevant oral, cardiovascular, gastrointestinal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow, dermatologic, hepatic, biliary, or renal dysfunction where, in the opinion of the Investigator or the Shire Study Physician, treatment with SSP-004184AQ is relatively contraindicated.
• Platelet count below 100,000/µL or absolute neutrophil count less than 1500/mm3 at the Qualification and Enrollment Visit.
• Known sensitivity to any ingredient in the SSP-004184AQ formulation.
• Pregnant or lactating females.
• For subjects that did not transition directly from their feeder protocol and have initiated treatment with a chelator other than SSP-004184AQ:
• In younger subjects for whom MRI is not feasible, evidence of severe cardiac dysfunction, as assessed by the Investigator.
• Non-elective hospitalization within the 30 days prior to receiving the first dose of SSP 004184AQ.
• For subjects greater than or equal to 18 years old: ALT greater than 200 IU/L at the Qualification and Enrollment Visit.
• OR For subjects less than 18 years old: ALT greater than 180 IU/L at the Qualification and Enrollment Visit.
• \- For subjects greater than or equal to 18 years old: Evidence of severe renal insufficiency, eg, serum creatinine 1.5X above the upper limit of normal or proteinuria greater than 1 gm per day or a calculated glomerular filtration rate less than 40 mL/min.
• OR For subjects less than 18 years old: Evidence of significant renal insufficiency, eg, serum creatinine above the upper limit of normal or proteinuria greater than 1 gm per day.

Sponsors & Collaborators

• Shire: lead

Study Sites (9)

Children's Hospital Oakland

Oakland, California, 94609, United States

Location

Children's Hospital of Boston

Boston, Massachusetts, 02115, United States

Location

The Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada

Location

Toronto General Hospital

Toronto, Ontario, M5G 2C4, Canada

Location

San Luigi Hospital Thalassemia Centre

Orbassano, Torino, 10043, Italy

Location

Ospedale Regionale Microcitemie

Cagliari, 09121, Italy

Location

Ospedale Galliera

Genova, 16128, Italy

Location

Siriraj Hospital, Mahidol University

Bangkok, 10700, Thailand

Location

Whittington Hospital

London, N19 5NF, United Kingdom

Location

Limitations and Caveats

This study was terminated early due to non-clinical safety results. Not all participants completed the study. The available efficacy data were analyzed as specified in the statistical analysis plan; however, no efficacy conclusions were drawn.

Results Point of Contact

• Title: Study Director
• Organization: Shire

ClinicalTransparency@shire.com

+1 866 842 5335

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 16, 2012
• First Posted: August 23, 2012
• Study Start: August 14, 2012
• Primary Completion: April 24, 2014
• Study Completion: April 24, 2014
• Last Updated: June 29, 2021
• Results First Posted: August 6, 2015

Record last verified: 2021-06

Locations

TH (1); CA (2); GB (1); US (2); IT (3)